A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

Tongji Hospital

Status and phase: Unknown; Phase 4

Conditions: 2019-nCoV

Treatments: Drug: Abidol hydrochloride; Drug: Oseltamivir; Drug: Lopinavir/ritonavir

Study type: Interventional

Funder types: Other

Identifiers

NCT04255017

TJ20200128

Details and patient eligibility

About

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. 2019-nCoV nucleic acid test was positive.
2. CT of the lung conformed to the manifestation of viral pneumonia.

Exclusion criteria

1. Patients who meet any of the contraindications in the experimental drug labeling
2. Patients who do not want to participate in this clinical study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

400 participants in 4 patient groups

Symptomatic supportive treatment

No Intervention group

Description:

Symptomatic supportive treatment

Abidol hydrochloride was added on the basis of group I.

Experimental group

Description:

Abidol hydrochloride 0.2g once,3 times a day,2 weeks

Treatment:

Drug: Abidol hydrochloride

Oseltamivir was added on the basis of group I.

Experimental group

Description:

Oseltamivir 75mg once,twice a day,2 weeks

Treatment:

Drug: Oseltamivir

Lopinavir/ritonavir was added on the basis of group I.

Experimental group

Description:

Lopinavir/ritonavir 500mg once,twice a day,2 weeks

Treatment:

Drug: Lopinavir/ritonavir